Previous to the publication of the EC proposal to review the EU pharmaceutical legislation, EPHA had called for more transparency of the research and development (R&D) costs for pharmaceutical products. Without clear knowledge of pharmaceutical R&D costs, it...
By Charlotte Roffiaen, France Assos Santé With the COVID-19 pandemic and the multiplication of antibiotic supply disruptions, the fight against medicine shortages has become one of the first priorities of the EU and its Member States. This is perfectly reflected in...
By Dr Ward Rommel, Chair, Access to Medicines Task Force of Association of European Cancer Leagues (ECL) – @CancerLeagues & @WardRommel | #LetsTalkAccess In Europe, around 2.7 million people are diagnosed with cancer every year – and this number is set to...
EPHA welcomes the European Commission’s proposal and calls for a balanced debate so that the legislation adopted serves the needs of all people living across the EU and not just the provision of incentives to the pharmaceutical sector. This lunchtime, the European...
Have you ever been to the pharmacy and couldn’t find the medicine you were looking for? Have you or your doctor struggled to find a medicine for you? Do you wonder why there are good new medicines for some diseases and no alternatives for others? In this episode, we...
